Alterity Therapeutics Limited Net Assets
Alterity Therapeutics Limited net assets. Based on the latest financial reports, Alterity Therapeutics Limited (PBN) has net assets worth €54.27 Million EUR (≈ $63.44 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€56.92 Million ≈ $66.54 Million USD) and total liabilities (€2.65 Million ≈ $3.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore PBN year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €54.27 Million |
| % of Total Assets | 95.34% |
| Annual Growth Rate | 1.08% |
| 5-Year Change | 39.16% |
| 10-Year Change | 35.18% |
| Growth Volatility | 115.48 |
Net Assets of Alterity Therapeutics Limited (2014–2025)
Net assets of Alterity Therapeutics Limited from 2014 to 2025. This chart illustrates how Alterity Therapeutics Limited's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Alterity Therapeutics Limited to measure how much of total assets are equity-financed.
Annual Net Assets for Alterity Therapeutics Limited (2014–2025)
The table below shows the annual net assets of Alterity Therapeutics Limited from 2014 to 2025. For live market cap and overall valuation, see Alterity Therapeutics Limited stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €42.40 Million ≈ $49.57 Million |
+207.31% |
| 2024-06-30 | €13.80 Million ≈ $16.13 Million |
-39.52% |
| 2023-06-30 | €22.81 Million ≈ $26.67 Million |
-35.68% |
| 2022-06-30 | €35.47 Million ≈ $41.47 Million |
+16.40% |
| 2021-06-30 | €30.47 Million ≈ $35.62 Million |
+326.11% |
| 2020-06-30 | €7.15 Million ≈ $8.36 Million |
-56.81% |
| 2019-06-30 | €16.55 Million ≈ $19.35 Million |
+2.95% |
| 2018-06-30 | €16.08 Million ≈ $18.80 Million |
-32.12% |
| 2017-06-30 | €23.69 Million ≈ $27.70 Million |
-24.48% |
| 2016-06-30 | €31.37 Million ≈ $36.67 Million |
-19.80% |
| 2015-06-30 | €39.11 Million ≈ $45.73 Million |
+3.79% |
| 2014-06-30 | €37.69 Million ≈ $44.06 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Alterity Therapeutics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11462811800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Alterity Therapeutics Limited Net Assets Breakdown (June 2025)
Alterity Therapeutics Limited net assets breakdown by equity component as of June 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €268.29 Million | 632.72% |
| Total Equity | €42.40 Million | 100.00% |
Alterity Therapeutics Limited Competitors by Market Cap
The table below lists competitors of Alterity Therapeutics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CAG Group AB (publ)
ST:CAG
|
$65.26 Million |
|
Aditya Birla Money Limited
NSE:BIRLAMONEY
|
$65.27 Million |
|
Duran-Dogan Basim ve Ambalaj Sanayi AS
IS:DURDO
|
$65.29 Million |
|
SYNergy ScienTech Corp
TW:6558
|
$65.30 Million |
|
Complex Micro Interconnection Co. Ltd.
TW:6835
|
$65.23 Million |
|
Gagasan Nadi Cergas Berhad
KLSE:0206
|
$65.22 Million |
|
DY Corporation
KO:013570
|
$65.20 Million |
|
Gold Terra Resource Corp
V:YGT
|
$65.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alterity Therapeutics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,798,057 to 42,403,086, a change of 28,605,029 (207.3%).
- Net loss of 12,147,828 reduced equity.
- New share issuances of 42,570,645 increased equity.
- Other factors decreased equity by 1,817,788.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-12.15 Million | -28.65% |
| Share Issuances | €42.57 Million | +100.4% |
| Other Changes | €-1.82 Million | -4.29% |
| Total Change | €- | 207.31% |
Book Value vs Market Value Analysis
This analysis compares Alterity Therapeutics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 31.00x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.25x to 31.00x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | €0.04 | €0.14 | x |
| 2018-06-30 | €0.03 | €0.14 | x |
| 2019-06-30 | €0.02 | €0.14 | x |
| 2020-06-30 | €0.01 | €0.14 | x |
| 2021-06-30 | €0.01 | €0.14 | x |
| 2022-06-30 | €0.01 | €0.14 | x |
| 2023-06-30 | €0.01 | €0.14 | x |
| 2024-06-30 | €0.00 | €0.14 | x |
| 2025-06-30 | €0.00 | €0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alterity Therapeutics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-28.65%) is above the historical average (-61.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -35.37% | -162.37% | 0.20x | 1.10x | €-17.10 Million |
| 2015 | -15.05% | -90.62% | 0.16x | 1.07x | €-9.80 Million |
| 2016 | -24.64% | -5418.28% | 0.00x | 1.08x | €-10.87 Million |
| 2017 | -31.84% | -5696.60% | 0.01x | 1.07x | €-9.91 Million |
| 2018 | -51.40% | -4108.75% | 0.01x | 1.16x | €-9.87 Million |
| 2019 | -74.53% | -11367.29% | 0.01x | 1.20x | €-13.99 Million |
| 2020 | -188.19% | 0.00% | 0.00x | 1.39x | €-14.17 Million |
| 2021 | -50.24% | 0.00% | 0.00x | 1.10x | €-18.36 Million |
| 2022 | -36.22% | 0.00% | 0.00x | 1.17x | €-16.39 Million |
| 2023 | -60.52% | 0.00% | 0.00x | 1.20x | €-16.09 Million |
| 2024 | -138.60% | 0.00% | 0.00x | 1.39x | €-20.50 Million |
| 2025 | -28.65% | 0.00% | 0.00x | 1.09x | €-16.39 Million |
Industry Comparison
This section compares Alterity Therapeutics Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alterity Therapeutics Limited (PBN) | €54.27 Million | -35.37% | 0.05x | $65.25 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more